ClinicalTrials.Veeva

Menu
A

AGILE Clinical Research Trials | Atlanta, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Elagolix
Estradiol
Norethindrone Acetate
Fezolinetant
Vilaprisan
Pregabalin
Gabapentin
Pomotrelvir
PBI-0451
BFKB8488A

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 29 total trials

A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

Active, not recruiting
Uterine Fibroids
Drug: Vilaprisan (BAY1002670)
Other: Standard of care

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease...

Enrolling
Celiac Disease
Dietary Supplement: Gluten
Drug: TAK-101

This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI-0451(Pomotrelvir)...

Active, not recruiting
COVID-19
Drug: PBI-0451 (Pomotrelvir)
Drug: Placebo

Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles

Active, not recruiting
Contraception
Drug: MR-100A-01

Trial sponsors

AbbVie logo
Astellas logo
Bayer logo
Gilead Sciences logo
Janssen (J&J Innovative Medicine) logo
A
Enanta Pharmaceuticals logo
E
Genentech logo
K

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems